Valuation: Exelixis, Inc.

Market Cap 14.2B 12.48B 11.65B 10.69B 20.01B 1,361B 20.51B 138B 54.03B 673B 53.33B 52.17B 2,327B P/E 2026 *
17.8x
P/E 2027 * 15.2x
Enterprise Value 13.38B 11.76B 10.98B 10.08B 18.86B 1,282B 19.32B 130B 50.91B 634B 50.25B 49.16B 2,193B EV / Sales 2026 *
5.16x
EV / Sales 2027 * 4.28x
Free-Float
98.18%
Yield 2026 *
-
Yield 2027 * -
1 day-2.09%
1 week+0.64%
Current month+1.69%
1 month+1.93%
3 months+23.81%
6 months+30.87%
Current year+26.24%
1 week 54.2
Extreme 54.2
56.86
1 month 53.25
Extreme 53.2481
57.57
Current year 39.71
Extreme 39.71
57.57
1 year 33.76
Extreme 33.755
57.57
3 years 18.64
Extreme 18.64
57.57
5 years 14.87
Extreme 14.87
57.57
10 years 9
Extreme 9
57.57
Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Date Insider Type Main position Quantity % Market Cap.
6/1/26 Sell

Director

-3,925 0.0016%
6/1/26 Sell

Director

-9,812 0.0039%
5/27/26 Free

Director

8,367 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
-2.09%+0.64%+49.78%+180.72% 14.2B
+0.47%+2.03%+51.54%+70.84% 55.01B
+2.83%+0.04%+38.07%+82.59% 54.24B
+0.54%+1.22%-16.62%-14.62% 23.38B
-0.97%-3.30%-1.79%+366.82% 22.57B
+2.07%+1.44%+23.06%-9.05% 20.19B
-2.15%+0.78%+24.67%-31.03% 17.86B
-2.14%-2.72%+30.26%+536.72% 15.5B
-3.14%-8.09%+160.68%+292.18% 14.2B
+1.50%+1.72%+85.76%+166.38% 12.42B
Average -0.18%-0.21%+44.54%+164.15% 24.96B
Weighted average by Cap. +0.45%-0.05%+39.67%+130.94%

Financials

2026 *2027 *
Net sales 2.6B 2.28B 2.13B 1.95B 3.66B 249B 3.75B 25.25B 9.88B 123B 9.75B 9.54B 425B 2.92B 2.57B 2.4B 2.2B 4.12B 280B 4.22B 28.45B 11.13B 139B 10.98B 10.74B 479B
Net income 812M 713M 666M 611M 1.14B 77.77B 1.17B 7.9B 3.09B 38.48B 3.05B 2.98B 133B 942M 828M 773M 709M 1.33B 90.25B 1.36B 9.16B 3.58B 44.66B 3.54B 3.46B 154B
Net Debt -819M -720M -672M -617M -1.15B -78.48B -1.18B -7.97B -3.12B -38.83B -3.08B -3.01B -134B -1.7B -1.49B -1.39B -1.28B -2.39B -163B -2.45B -16.5B -6.45B -80.41B -6.37B -6.23B -278B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
26-07-29 $55.33 -2.09% 1,881,967
26-07-28 $56.51 +1.25% 2,489,469
26-07-27 $55.81 +0.79% 2,316,906
26-07-24 $55.37 -0.50% 1,838,009
26-07-23 $55.65 +1.22% 1,659,664
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
56.51USD
Average target price
52.07USD
Spread / Average Target
-7.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock